Literature DB >> 28713874

Gender Differences in Non-Toxigenic Clostridium difficile Colonization and Risk of Subsequent C. difficile Infection.

Mukil Natarajan1, Mary Am Rogers1, Jacob Bundy2, Dejan Micic1, Seth T Walk1,3, Kavitha Santhosh1, Krishna Rao1, Spencer Winters1, Vincent B Young1,4, David M Aronoff1,5.   

Abstract

OBJECTIVES: Previous studies suggest that colonization with non-toxigenic Clostridium difficile may protect against toxigenic C. difficile infection (CDI), yet most of the studies were conducted in men. Therefore, we conducted a study to examine this hypothesis in both genders.
METHODS: Patients (n=1492) were classified by disease status at baseline and observed for 1 year. Cox proportional hazards regression was used to evaluate CDI rates within 8 weeks post-baseline (short-term) and from 8 weeks to 1 year (long-term follow-up).
RESULTS: During short-term follow-up, CDI rates were 5 times greater in females with non-toxigenic Clostridium difficile compared to females without C. difficile (hazard ratio (HR) = 5.13; 95% CI: 1.47-17.83). The comparable HR in males was 0.44 (95% CI: 0.04-4.43). During long term follow-up, CDI rates were similar in those with non-toxigenic C. difficile and those without C. difficile at baseline, for both females and males. Mortality rates were significantly lower for patients colonized by non-toxigenic C. difficile than those with toxigenic C. difficile at baseline, for both genders combined (HR=0.51; 95% CI: 0.28-0.92) and were similar to those with no C. difficile at baseline (HR=0.78; 95% CI: 0.43-1.41).
CONCLUSIONS: There were gender differences in the short-term risk of CDI. Mortality was similar for patients colonized with non-toxigenic C. difficile and patients without C. difficile.

Entities:  

Keywords:  Clostridium difficile; Gender; Infection; Mortality; Non-toxigenic strains

Year:  2015        PMID: 28713874      PMCID: PMC5508598     

Source DB:  PubMed          Journal:  Clin Res Infect Dis


  36 in total

1.  Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study.

Authors:  Susanne Mueller; Katiana Saunier; Christiana Hanisch; Elisabeth Norin; Livia Alm; Tore Midtvedt; Alberto Cresci; Stefania Silvi; Carla Orpianesi; Maria Cristina Verdenelli; Thomas Clavel; Corinna Koebnick; Hans-Joachim Franz Zunft; Joël Doré; Michael Blaut
Journal:  Appl Environ Microbiol       Date:  2006-02       Impact factor: 4.792

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

3.  Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.

Authors:  D Seal; S P Borriello; F Barclay; A Welch; M Piper; M Bonnycastle
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

4.  Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.

Authors:  Janet G M Markle; Daniel N Frank; Steven Mortin-Toth; Charles E Robertson; Leah M Feazel; Ulrike Rolle-Kampczyk; Martin von Bergen; Kathy D McCoy; Andrew J Macpherson; Jayne S Danska
Journal:  Science       Date:  2013-01-17       Impact factor: 47.728

5.  Colonization for the prevention of Clostridium difficile disease in hamsters.

Authors:  Susan P Sambol; Michelle M Merrigan; Janet K Tang; Stuart Johnson; Dale N Gerding
Journal:  J Infect Dis       Date:  2002-11-22       Impact factor: 5.226

6.  Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile.

Authors:  Kristin J Nagaro; S Tyler Phillips; Adam K Cheknis; Susan P Sambol; Walter E Zukowski; Stuart Johnson; Dale N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

7.  Symbiotic gut microbes modulate human metabolic phenotypes.

Authors:  Min Li; Baohong Wang; Menghui Zhang; Mattias Rantalainen; Shengyue Wang; Haokui Zhou; Yan Zhang; Jian Shen; Xiaoyan Pang; Meiling Zhang; Hua Wei; Yu Chen; Haifeng Lu; Jian Zuo; Mingming Su; Yunping Qiu; Wei Jia; Chaoni Xiao; Leon M Smith; Shengli Yang; Elaine Holmes; Huiru Tang; Guoping Zhao; Jeremy K Nicholson; Lanjuan Li; Liping Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-05       Impact factor: 11.205

8.  New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration.

Authors:  Michelle M Merrigan; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  Int J Antimicrob Agents       Date:  2009-03       Impact factor: 5.283

9.  Clinical risk factors for severe Clostridium difficile-associated disease.

Authors:  Timothy J Henrich; Douglas Krakower; Asaf Bitton; Deborah S Yokoe
Journal:  Emerg Infect Dis       Date:  2009-03       Impact factor: 6.883

10.  Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers.

Authors:  Michael S M Brouwer; Adam P Roberts; Haitham Hussain; Rachel J Williams; Elaine Allan; Peter Mullany
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  3 in total

Review 1.  Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review.

Authors:  Yuanbin Liu; Mingkai Chen
Journal:  Can J Gastroenterol Hepatol       Date:  2022-06-07

2.  THAs Performed Within 6 Months of Clostridioides difficile Infection Are Associated with Increased Risk of 90-Day Complications.

Authors:  Scott J Douglas; Ethan A Remily; Oliver C Sax; Sahir S Pervaiz; Evan B Polsky; Ronald E Delanois
Journal:  Clin Orthop Relat Res       Date:  2021-12-01       Impact factor: 4.176

3.  Characteristics, Risk Factors, and Prevalence of Clostridioides difficile Among Hospitalized Patients in a Tertiary Care Hospital in Palestine.

Authors:  Abdallah Damin Abukhalil; Liana AbuKhdeir; Malak Hamed; Ni'meh Al Shami; Hani A Naseef; Banan M Aiesh; Ali Sabateen
Journal:  Infect Drug Resist       Date:  2021-11-09       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.